SCM
SUPN icon

Silvant Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Silvant Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,576
Closed -$195K – 342
2019
Q1 		$195K Hold
5,576
– – 0.04% 190
2018
Q4 		$185K Sell
5,576
-2,695
-33% -$116K 0.04% 185
2018
Q3 		$416K Hold
8,271
– – 0.05% 137
2018
Q2 		$495K Hold
8,271
– – 0.06% 122
2018
Q1 		$379K Buy
+8,271
New +$345K 0.05% 140

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
NPIC
Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

Silvant Capital Management's SUPN Position: Q2 2019 in Review

Silvant Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2019, closing a stake of 5,576 shares — an estimated $195K sold.

Silvant Capital Management first reported a position in SUPN in Q1 2018 and held it in 5 quarters. The position peaked at $495K in Q2 2018. 272 funds tracked by Wall St. Rank hold SUPN as of Q2 2019.

  • Silvant Capital Management reported no remaining Supernus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Silvant Capital Management sold 5,576 Supernus Pharmaceuticals shares in Q2 2019, an estimated $195K.
  • Silvant Capital Management first reported a position in Supernus Pharmaceuticals in Q1 2018 and held it in 5 quarters.
  • Silvant Capital Management's Supernus Pharmaceuticals position peaked at $495K in Q2 2018.
  • 272 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2019.

Based on Silvant Capital Management's 13F filing for Q2 2019, filed 9 Aug 2019.